Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Accelerating clinical trials: time to turn words into action.

Landray MJ. et al, (2023), Lancet, 402, 165 - 168

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.

Zhou J. et al, (2023), Pharmacoeconomics

Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association's Scientific Sessions 2022 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2022.

(2022), Circulation, 146, e569 - e605

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.

Cholesterol Treatment Trialists' Collaboration None., (2022), Lancet, 400, 832 - 845

Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials.

Pitcher A. et al, (2022), Lancet

Individual participant data meta-analysis of muscle symptoms in large-scale randomised double-blind trials of statin therapy

BAIGENT C. et al, (2022), The Lancet

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.

RECOVERY Collaborative Group None., (2022), Lancet, 400, 359 - 368

Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy.

Cholesterol Treatment Trialists' Collaboration None., (2022), Clin Trials

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 665 - 676

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2022), Lancet, 399, 143 - 151

CALIBRATING CARDIOVASCULAR DISEASE POLICY MODEL USING LARGE COHORT DATA

Wu R. et al, (2022), VALUE IN HEALTH, 25, S16 - S16

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials.

Staplin N. et al, (2021), EClinicalMedicine, 41

A model of lifetime health outcomes in cardiovascular disease based on clinical trials and large cohorts

Wu R. et al, (2021), EUROPEAN HEART JOURNAL, 42, 3149 - 3149

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 2049 - 2059

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 1637 - 1645

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612

A pragmatic tool for drug discovery.

Bobbitt DR. et al, (2020), Drug Discov Today

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors: JACC Focus Seminar.

Preiss D. et al, (2020), J Am Coll Cardiol, 75, 1945 - 1955

Load More

Include forthcoming?